PhI fiz­zle forces Sy­ros to spike its lead drug, trig­ger­ing an­oth­er rout on shares

Less than stel­lar Phase I re­sults have trig­gered a pipeline cleanup at Sy­ros Phar­ma, where one of its two lead drugs — a CDK7 in­hibitor ad­min­is­tered …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.